These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33050272)

  • 21. Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.
    Sun C; Wang X; Zhang R; Xu L; Wang B; Li J
    Cancer Cell Int; 2022 Jul; 22(1):222. PubMed ID: 35788237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
    Hassan H; Anwer F; Javaid A; Hashmi H
    Crit Rev Oncol Hematol; 2021 Sep; 165():103435. PubMed ID: 34343658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
    Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and Treatment of AL Amyloidosis.
    Palladini G; Milani P
    Drugs; 2023 Feb; 83(3):203-216. PubMed ID: 36652193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resolving the daratumumab interference with blood compatibility testing.
    Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
    Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report.
    Li X; Pan XH; Fang Q; Liang Y
    World J Clin Cases; 2022 Dec; 10(34):12703-12710. PubMed ID: 36579116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
    Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.
    Werle E; Ziebart J; Wasmund E; Eske-Pogodda K
    Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.
    Padmaraju K; Kelly K; Jakubowiak AJ; Derman BA
    Oncologist; 2024 Jun; ():. PubMed ID: 38920281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
    Milani P; Fazio F; Basset M; Berno T; Larocca A; Foli A; Riva M; Benigna F; Oliva S; Nuvolone M; Rodigari L; Petrucci MT; Merlini G; Palladini G
    Am J Hematol; 2020 Aug; 95(8):900-905. PubMed ID: 32282971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.
    Wang Y; Xu L; Zhao W; Chen X; Wen L; Duan W; Yu XJ; De Zhou F; Liu Y; Hao J; Huang X; Lu J; Ge Q
    Clin Transl Med; 2021 Nov; 11(11):e582. PubMed ID: 34845849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on the role of daratumumab in the treatment of multiple myeloma.
    Costello C
    Ther Adv Hematol; 2017 Jan; 8(1):28-37. PubMed ID: 28042457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
    Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
    Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.
    Vitkon R; Netanely D; Levi S; Ziv-Baran T; Ben-Yzak R; Katz BZ; Benyamini N; Trestman S; Mittelman M; Cohen Y; Avivi I
    Ther Adv Hematol; 2021; 12():20406207211035272. PubMed ID: 34377384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
    Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
    Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary AL amyloidosis: A review and update on treatment options.
    Moy LN; Mirza M; Moskal B; Asado N; Shah B; Bitran J
    Ann Med Surg (Lond); 2022 Aug; 80():104060. PubMed ID: 35855884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
    Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
    J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
    Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
    Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.